Document Detail

Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
MedLine Citation:
PMID:  22521084     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Along with environmental risk factors such as smoking, hypertension, and atherosclerosis, genetic susceptibility is a primary contributor to the development and progression of exudative age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is a central angiogenic regulator and there has been general agreement now that it is an important trigger for the progression of exudative AMD. In the present study, we tested the hypothesis that VEGF gene polymorphisms play a role in the treatment success with VEGF inhibitors in patients with exudative AMD.
DESIGN: Prospective cohort study.
PARTICIPANTS: We included 185 eyes of 141 patients with exudative AMD who were scheduled for their first treatment with intravitreally administered bevacizumab in this trial.
METHODS: All patients were aged >50 years and had angiographically verified exudative AMD. Blood from the finger pad was collected on blood cards for genotyping for the VEGF polymorphisms rs1413711, rs3025039, rs2010963, rs833061, rs699947, rs3024997, and rs1005230. At each follow-up visit, visual acuity was reassessed and an ophthalmic examination was carried out. Visual acuity outcome, number of retreatments, and overall time of treatment were analyzed in dependence of the VEGF polymorphisms.
MAIN OUTCOME MEASURES: Mean change in visual acuity at the end of the treatment period.
RESULTS: The included patients were reinjected with bevacizumab 1 to 15 times, resulting in a total treatment period of 42 to 1182 days. In univariate analysis only the G/G genotypes of rs3024997 and rs2010963 compared with all other 5 single nucleotide polymorphisms (SNPs) showed a significantly lower visual acuity at the end of treatment. In multivariate analysis including parameters such as time, baseline visual acuity, and number of reinjections, none of the SNPs showed a significant correlation.
CONCLUSIONS: The current study indicates that VEGF polymorphisms are not major predictors of anti-VEGF treatment success in patients with exudative AMD.
Agnes Boltz; Manuel Ruiß; Jost B Jonas; Yong Tao; Florian Rensch; Martin Weger; Gerhard Garhöfer; Sophie Frantal; Yosuf El-Shabrawi; Leopold Schmetterer
Related Documents :
9212024 - Adaptive modification of treatment planning to minimize the deleterious effects of trea...
2296814 - Cavernosometry: corroboratory method to surgical treatment of impotence due to venous l...
3886214 - Prevention of recurrent variceal bleeding: non-surgical procedures.
9773214 - Asymptomatic esophageal varices should be endoscopically treated.
24105084 - The embrace device significantly decreases scarring following scar revision surgery in ...
10672114 - Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep ve...
Publication Detail:
Type:  Journal Article     Date:  2012-04-21
Journal Detail:
Title:  Ophthalmology     Volume:  119     ISSN:  1549-4713     ISO Abbreviation:  Ophthalmology     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-03     Completed Date:  2012-10-25     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  7802443     Medline TA:  Ophthalmology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1615-20     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use
Cohort Studies
Fluorescein Angiography
Intraocular Pressure
Intravitreal Injections
Middle Aged
Polymorphism, Single Nucleotide*
Prospective Studies
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors,  genetics*
Visual Acuity / physiology
Wet Macular Degeneration / drug therapy*,  genetics*,  physiopathology
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Risk Factors for Moderate and Severe Microbial Keratitis in Daily Wear Contact Lens Users.
Next Document:  Glaucoma Risk Alleles at CDKN2B-AS1 Are Associated with Lower Intraocular Pressure, Normal-Tension G...